Additional Relevant Details "We believe the final recommendations provide an important level of clarity to patients, physicians and insurers and that Cologuard should receive the benefits given to A-rated preventive services under the Affordable Care Act," said Kevin Conroy, Exact Sciences' chairman and CEO. "We thank the Task Force for carefully reviewing the body of scientific evidence supporting Cologuard and for providing this clear guidance."